Evidence map›Paper›PMID 37391501›Full record

ArticleScientific reports2023

A universal UHPLC-CAD platform for the quantification of polysaccharide antigens.

A Corrado, M De Martino, V Bordoni, S Giannini, F Rech, S Cianetti, F Berti, C Magagnoli, R De Ricco

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A CorradoTechnical R&D, GSK Via Fiorentina, 1, Siena, Italy.
M De MartinoTechnical R&D, GSK Via Fiorentina, 1, Siena, Italy.
V BordoniTechnical R&D, GSK Via Fiorentina, 1, Siena, Italy.
S GianniniTechnical R&D, GSK Via Fiorentina, 1, Siena, Italy.
F RechTechnical R&D, GSK Via Fiorentina, 1, Siena, Italy.
S CianettiTechnical R&D, GSK Via Fiorentina, 1, Siena, Italy.
F BertiTechnical R&D, GSK Via Fiorentina, 1, Siena, Italy.
C MagagnoliTechnical R&D, GSK Via Fiorentina, 1, Siena, Italy.
R De RiccoTechnical R&D, GSK Via Fiorentina, 1, Siena, Italy. riccardo.x.de-ricco@gsk.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several glycoconjugate-based vaccines against bacterial infections have been developed and licensed for human use. Polysaccharide (PS) analysis and characterization is therefore critical to profile the composition of polysaccharide-based vaccines. For PS content quantification, the majority of Ultra High Performance Liquid Chromatography (UHPLC) methods rely on the detection of selective monosaccharides constituting the PS repeating unit, therefore requiring chemical cleavage and tailored development: only a few methods directly quantify the intact PS. The introduction of charged aerosol detector (CAD) technology has improved the response of polysaccharide analytes, offering greater sensitivity than other detector sources (e.g., ELSD). Herein, we report the development of a universal UHPLC-CAD method (UniQS) for the quantification and quality evaluation of polysaccharide antigens (e.g., Streptococcus Pneumoniae, Neisseria meningitidis and Staphylococcus aureus). This work laid the foundation for a universal UHPLC-CAD format that could play an important role in future vaccine research and development helping to reduce time, efforts, and costs.

Indexed as

MonosaccharidesNeisseria meningitidisAerosolsChromatography, High Pressure LiquidHumansPolysaccharidesAerosolsMonosaccharidesPolysaccharides

Identifiers

PMID37391501
PMCPMC10313704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.